Drug intelligence / Profile preview

Bionerv

Development stage: Phase 3
Lead developer: Invision Medi Sciences
Modality: Small Molecules
Administration: Oral

Overview

Bionerv is an oral, film-coated tablet containing a fixed-dose combination of alpha lipoic acid (300mg), vitamin B12 (methylcobalamin 500mcg), vitamin B6 (pyridoxine 8mg), and vitamin B1 (thiamine 39mg). It is manufactured by BREGO Life Sciences Sdn Bhd and is being investigated for the treatment of diabetic polyneuropathy in individuals with type 2 diabetes mellitus. The product is described as the first combination of alpha lipoic acid and vitamin B complex.

Brand names: Bionerv
Other names: Alpha-lipoic acid + Vitamin B complexAlpha-Lipoic Acid/Vitamin/Mineral Supplement PolyMVA

Targets

α-KGDH (Alpha-ketoglutarate dehydrogenase complex)MTR (Methionine synthase)MMUT (Methylmalonyl-coenzyme A mutase)OADHCs (Mitochondrial lipoamide-dependent dehydrogenase complexes)PDH (Pyruvate dehydrogenase complex)TKT (Transketolase)

Beyond the preview

Go deeper on Bionerv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionerv.